NICM
PCVX icon

Neo Ivy Capital Management’s Vaxcyte PCVX Stock Holding History

Neo Ivy Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,803
Closed -$222K – 461
2025
Q4 		$222K Sell
4,803
-78,307
-94% -$3.5M 0.04% 270
2025
Q3 		$2.99M Buy
83,110
+58,869
+243% +$1.95M 0.73% 31
2025
Q2 		$788K Buy
+24,241
New +$795K 0.25% 141

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Neo Ivy Capital Management's PCVX Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 4,803 shares — an estimated $222K sold.

Neo Ivy Capital Management first reported a position in PCVX in Q2 2025 and held it in 3 quarters. The position peaked at $2.99M in Q3 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Neo Ivy Capital Management reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 4,803 Vaxcyte shares in Q1 2026, an estimated $222K.
  • Neo Ivy Capital Management first reported a position in Vaxcyte in Q2 2025 and held it in 3 quarters.
  • Neo Ivy Capital Management's Vaxcyte position peaked at $2.99M in Q3 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.